CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Aripiprazole +1 moredrug
Likely dose
Aripiprazole 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00489866
NCT00489866Phase 2Completed
CompareCT.gov

Aripiprazole Augmentation of Antidepressants in PTSD

Durham VA Medical Center·interventional·Posted Jun 21, 2007·Updated Mar 31, 2015

In Brief

A Phase 2 clinical trial evaluating Aripiprazole and Placebo for PTSD. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The proposed investigation will determine the therapeutic potential of aripiprazole augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder (PTSD) symptoms, cognitive symptoms, psychotic symptoms, and depressive symptoms in veterans with PTSD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 21, 2007
Enrollment StartMar 1, 2007
Primary CompletionSep 1, 2008
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.0 years ago

Interventions

Aripiprazoledrug

Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks

Placebodrug

Same as active drug.